New drug takes on KRAS: early trial launches for Hard-to-Treat cancers
NCT ID NCT04111458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called BI 1701963, which blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not responded to prior chemotherapy. The main goals are to find a safe dose and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1701963 (a KRAS-blocking drug) and trametinib (a MEK inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have a KRAS mutation.
What could go wrong
This is a very early (Phase 1) trial testing a new drug in humans for the first time. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Sarah Cannon Research Institute-Nashville-48456
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60590, Germany
-
Universitätsklinikum Köln (AöR)
Cologne, 50937, Germany